Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Montreux Equity Partners
AddedFeb 13, 2024
UpdatedJun 28, 2026
Montreux Equity Partners

Montreux Equity Partners

Operating

Montreux Equity Partners: A private investment firm, fueling the growth of tomorrow's leading companies since 1993.

Location
San Francisco, CA, US
Founded
1993
Firm
Compare
Portfolio
Employees
Website

Investments

Tebra
Tebra

Total Raised

$137M

Rounds

3

Series B$72MJuly 2022
KEO World
KEO World

Total Raised

$520M

Rounds

2

Series Unknown$20MJune 2022
FinPay
FinPay

Total Raised

$21.9M

Rounds

3

Series D$15MMarch 2022
Series C$5MNovember 2020
TigerConnect
TigerConnect

Total Raised

$448.9M

Rounds

8

Series D$45MOctober 2020
Pulmonx
Pulmonx
Public

Total Raised

$276.9M

Rounds

12

Series G$65MMay 2019
Private Equity$10MJanuary 2012
Series C$32MMarch 2010
Series B$20MMay 2007
Sonoma Pharmaceuticals
Sonoma Pharmaceuticals
Public

Total Raised

$77.9M

Rounds

5

Post Ipo Equity$4.6MMarch 2018
Pure Life Renal
Pure Life Renal

Total Raised

$21M

Rounds

3

Series A$20MMay 2014
Epirus Biopharmaceuticals
Epirus Biopharmaceuticals
Public

Total Raised

$83.1M

Rounds

5

Series B$36MApril 2014
Series Unknown$5MJuly 2012
Series Unknown$8.1MApril 2012
Glaukos
Glaukos
Public

Total Raised

$121M

Rounds

8

Series F$30MFebruary 2013
Series E$29.5MFebruary 2011
Series D$35MAugust 2008
Avantis Medical Systems
Avantis Medical Systems

Total Raised

$57.6M

Rounds

10

Debt Financing$2.8MJune 2010
Series B$12MNovember 2006
Moksha8
Moksha8

Total Raised

$224.1M

Rounds

5

Series B$25.1MDecember 2009
Novostent
Novostent

Total Raised

$14.4M

Rounds

3

Series Unknown$1.1MJune 2009
Domain Associates
Domain Associates

Total Raised

$97.2M

Rounds

6

Series D$30MNovember 2007
Series D$30MSeptember 2007
Sequel Pharmaceuticals
Sequel Pharmaceuticals

Total Raised

$25.4M

Rounds

4

Series A$20MSeptember 2007
KFx Medical
KFx Medical
Acquired

Total Raised

$23M

Rounds

6

Series B$10MAugust 2007